Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

70 results about "Galantamine" patented technology

Galantamine is used to treat mild to moderate confusion (dementia) related to Alzheimer's disease.

Galantamine formulations

Galantamine formulations, including sustained-release and fast dissolve formulations, are described.
Owner:ACTAVIS GRP PTC EHF

Compositions and methods using acetylcholinesterase (ACE) inhibitors to treat central nervous system (CNS) disorders in mammals

Methods and compositions of the invention employ acetylcholinesterase (ACE) inhibitors to prevent and treat diseases and other disorders of the central nervous system (CNS), including Alzheimer's disease. ACE inhibitors are administered for targeted delivery to the CNS, for example by intranasal delivery. The methods and compositions of the present invention yield therapeutic concentrations of ACE inhibitors in a CNS tissue or compartment without the attendant disadvantages, risks and side effects of oral or injection delivery. Exemplary ACE inhibitors for use within the invention include galantamine and various salts and derivatives of galantamine. Carboxylate salts of galantamine (e.g., galantamine gluconate, galantamine lactate, galantamine citrate and galantamine glucarate) described herein exhibit a significant increase in solubility compared to other forms of galantamine, such as galantamine hydrobromide.
Owner:NASTECH PHARMA

Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment

The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline, and their exogenous agonists, of neuronal cholinergic receptors and / or acting as cholinesterase inhibitors and / or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally by their chemical structure or directly by chemical synthesis) from natural compounds belonging to the class of amaryllidaceae alkaloids e.g., galantamine, narwedine and lycoramine, or from metabolites of said compounds. The compounds of the present invention can either interact as such with their target molecules, or they can act as “pro-drugs”, in the sense that after reaching their target regions in the body they are converted by hydrolysis or enzymatic attack to the original parent compound and react as such with their target molecules, or both. The compounds of this invention may be used as medicaments.
Owner:GALANTOS PHARMA

Cholinesterase Inhibitors In Liposomes And Their Production And Use

The invention relates to a pharmaceutical composition based on an active ingredient that is enclosed in liposomes for topical, transdermal application. The interior of said liposomes comprises an acidic, aqueous medium containing at least one cholinesterase inhibitor, preferably from the group containing donepezil, rivastigmine, galantamine, physostigmine, heptylphysostigmine, phenserine, tolserine, cymserine, thiatolserine, thiacymserine, neostigmine, huperzine, tacrine, metrifonate and dichlorvos, or an enantiomer or derivative of at least one of said compounds. In addition, the invention relates to a method for producing said composition, optionally in a sterile form and also to the use of the liposomes charged with the active ingredient in various galenic formulations for topical, transdermal application with a depot effect in the epidermis, for the prophylaxis and / or treatment of cutaneous neuropathic pain or the loss of cutaneous sensory function as a result of neuropathy.
Owner:SANOCHEMIA PHARMA AG

Controlled-release galantamine formulations

Controlled-release galantamine formulations, including controlled-release particles, pellets, granules, and spheres are described. Controlled-release particles, pellets, granules, and spheres with immediate release top-coat are also described. Method of preparing such formulations and method of treating a variety of disorders are also disclosed.
Owner:ACTAVIS GRP PTC EHF

Pharmaceutical compositions and methods for treating Alzheimer's disease

A pharmaceutical composition containing the therapeutically active ingredients of azelastine or a pharmaceutically acceptable salt of azelastine and donepezil or rivastigmine or galantamine or a pharmaceutically acceptable salt of thereof is disclosed. A method of using the pharmaceutical composition for treating patients suffering from mental, behavioral, cognitive disorders is also disclosed.
Owner:LA PHARMATECH INC

Galantamine formulations

Galantamine formulations substantially free of microcrystalline cellulose, lactose, and / or starch are described.
Owner:ACTAVIS GRP PTC EHF

CDK5 genetic markers associated with galantamine response

Haplotypes in the CDK5 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CDK5 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CDK5 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his / her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.
Owner:PGXHEALTH

Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment

The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline, and their exogenous agonists, of neuronal cholinergic receptors and / or acting as cholinesterase inhibitors and / or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally by their chemical structure or directly by chemical synthesis) from natural compounds belonging to the class of amaryllidaceae alkaloids e.g., galantamine, narwedine and lycoramine, or from metabolites of said compounds. The compounds of the present invention can either interact as such with their target molecules, or they can act as “pro-drugs”, in the sense that after reaching their target regions in the body they are converted by hydrolysis or enzymatic attack to the original parent compound and react as such with their target molecules, or both. The compounds of this invention may be used as medicaments.
Owner:NEURODYN LIFE SCI

Galantamine tablet formulation

The present invention relates to a direct compression tablet formulation comprising, as the active ingredient, galantamine, and more specifically, galantamine hydrobromide along with a process of making the same. The tablet formulation is a direct compression tablet and has excellent content uniformity and dissolution properties.
Owner:ROXANE LAB

Application of puerarin or medicinal composition containing puerarin in preparation of medicament with effect of preventing or treating senile dementia

The invention discloses application of puerarin or a medicinal composition containing the puerarin in preparation of a medicament with an effect of preventing or treating senile dementia. The puerarin can be singly used as a medicament or can be used together with other senile dementia medicaments with different mechanisms of action when used for treating or preventing the senile dementia of people or mammals, wherein the puerarin not only can reduce side or toxic effects of medicaments but also can achieve an effective of collaborative treatment when used for treating the senile dementia together with a medicinal composition consisting of triptolide, galantamine and borneol. The puerarin can significantly inhibit the deposition of beta-amyloid, and has a definite curative effect and small side effects when used for preventing and treating the senile dementia, so that the puerarin has a wide medical application prospect.
Owner:INFINITUS (CHINA) CO LTD

CDK5 genetic markers associated with galantamine response

Haplotypes in the CDK5 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CDK5 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CDK5 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his / her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.
Owner:PGXHEALTH

CHRNA2 genetic markers associated with galantamine response

Haplotypes in the CHRNA2 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CHRNA2 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CHRNA2 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his / her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.
Owner:PGXHEALTH

EPHX2 Genetic markers associated with galantamine

Haplotypes in the EPHX2 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these EPHX2 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these EPHX2 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his / her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.
Owner:PGXHEALTH

Use of galantamine for the treatment of neuropsychiatric behaviour associated with Alzheimer's disease

Galantamine has be used in the treatment of a number of chronic diseases. Galantamine has been found to be safe and effective in the treatment of Alzheimer's disease. Neuropsychiatric disorders are often associated with Alzheimer's disease. It is demonstrated that galantamine is also effective in reducing or stabilizing the incidence of neuropsychiatric behaviour seen in Alzheimer's patients.
Owner:PARYS WIM LOUIS JULIEN +1

LRPAP1 genetic markers associated with galantamine

Haplotypes in the LRPAP1 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these LRPAP1 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these LRPAP1 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his / her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.
Owner:PGXHEALTH

Galantamine clearance of amyloid-beta

Galantamine and its pharmaceutically acceptable salts are of use in treating persons meeting criteria for having a risk of developing Alzheimer's type dementia, before dementia occurs by reducing thedecline of A[beta] amyloid in CSF or the increase in cortical beta amyloid, in order to delay cognitive decline.
Owner:SYNAPTEC DEV

Modulation of Microglial by Nicotinic Medications

A method of treating a subject suffering from a neurodegenerative disease by modulating microglial activation with a therapeutically effective amount of a cholinergic agonist and a cholinesterase inhibitor. In one embodiment of the invention, the cholinergic agonist is nicotine and the cholinesterase is galantamine (a relatively weak acetylcholinesterase inhibitor and a potent allosteric potentiating ligand of nAChRs)
Owner:UNIV OF SOUTH FLORIDA

Reagent and kit for enriching breast cancer stem cells from breast cancer cell strains

The invention discloses a reagent and kit for enriching breast cancer stem cells from breast cancer cell strains. The reagent includes galantamine and lycorine as a screening agent. The breast cancer cell strains are MCF-7 breast cancer cell strains. The kit comprises a double-antibody, galantamine and lycorine as a screening agent, a screening-agent-dissolving auxiliary agent, sodium sulfite as an anti-oxidant, a recombinant human epidermal growth factor (EFG) which is a conventional growth factor, bovine serum albumin (BSA), insulin and B27. The provided reagent can enrich breast cancer stem cells from human breast cancer MCF-7 cell strains in a convenient, fast and efficient way, the cell spheroids are short in forming period, and the content of cancer cells and SP cells marked by CD44<+>CD24<- / low> molecules in microsphere cells is high. The developed kit can improve the efficiency for enriching cancer stem cells by science researchers.
Owner:南京千年健干细胞基因工程有限公司

Use of galantamine for treatment of neuropsychiatric behaviour associated with alzheimer's disease

Galantamine has been used in the treatment of a number of chronic diseases. Galantamine has been found to be safe and effective in the treatment of Alzheimer's disease. Neuropsychiatric disorders are often associated with Alzheimer's disease. It is demonstrated that galantamine is also effective in reducing or stabilizing the incidence of neuropsychiatric behaviour seen in Alzheimer's patients.
Owner:JANSSEN PHARMA NV

Synthesis method of galanthamine

The invention provides a new method for the preparation of (-)-galanthamine. The method includes the following steps: preparing N-methyl-N-(4-hydroxyl phenethyl)-3-hydroxyl-4-methoxyl-6-bretylium (f) by condensation of N-(4-hydroxyl phenethyl)-3-hydroxyl-4-methoxyl-6-bretylium (d) as a starting material and formaldehyde, then preparing bromo-narwedine (g) by catalytic oxidation using an oxidizing agent (Oxone / CaCl2 / TEMPO) and a phase-transfer catalyst, transforming the bromo-narwedine to levo bromo-narwedine (h) by Shieh method, obtaining bromo-(-)-galantamine (i) by asymmetric reduction, and then obtaining the (-)-galanthamine by hydrogenated debromination.
Owner:TIANJIN HAIGELI TECH DEV

Compound medicinal composition containing acetylcholinesterase inhibitor and metformin

The invention belongs to the technical field of medicine, and specifically relates to a compound medicinal composition with acetylcholinesterase inhibitors such as donepezil, galantamine or huperzine A and metformin as active ingredients, a preparation method thereof and a therapeutic use thereof. Pharmacodynamic tests show that the compound pharmaceutical composition of the present invention can be used for the prevention and treatment of Alzheimer's dementia, and the combined use of the compound medicine has a synergistic effect in curative effect.
Owner:南京千手共创生物科技有限公司 +1

Method for detecting galantamine in lycoris aurea

The invention discloses a method for detecting galantamine in lycoris aurea, and relates to plant sample handling, preparation of a nanogold printing electrode sensor and electrochemical detection. According to the method, the nanogold-modified printing electrode sensor is adopted to fully absorb in a sample extracting solution, then the nanogold printing electrode sensor is subjected to differential pulse voltammetry scanning to measure current values at oxidation peaks, within a detectable range, the content of the galantamine in the lycoris aurea absorbed by the nanogold printing electrodesensor is in a linear relation with the current intensities at the oxidation peaks, and according to a working curve, the content of the galantamine in the detected lycoris aurea can be calculated. The method has the advantages that the nanotechnology and the silk-screen printing technology are combined by the prepared nanogold printing electrode sensor, sensitivity, in galantamine concentration detection, of the sensor can be improved remarkably, and the minimum limit of detection of the sensor can reach to 0.013 microns.
Owner:上海联星医药科技有限公司

Galantamine clearance of amyloid ß

PendingUS20180200259A1Lower Level RequirementsDelaying the onset of such dementiaNervous disorderHeterocyclic compound active ingredientsCerebrospinal fluidAβ amyloid
Galantamine and its pharmaceutically acceptable salts are of use in treating persons meeting criteria for having a risk of developing Alzheimer's type dementia, before dementia occurs by reducing the decline of Aβ amyloid in CSF or the increase in cortical beta amyloid, in order to delay cognitive decline.
Owner:SYNAPTEC DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products